Tag: Fate Therapeutics (NASDAQ: FATE)


Analysts Reflect On Various Pharmaceutical Companies Following The End of ASCO

With the American Society of Clinical Oncology Annual Meeting coming to an end, there was a range of abstract presentation highlights for biotech and pharma investors and analysts.¬† Tazeen Ahmad gives Buy rating to Fatem Incyte and ADC therapeutics¬† For instance, BoA Securities analyst Tazeen Ahmad highlighted several companies, including […]